InvestSMART

Imagion Biosystems Limited (ASX:IBX)

ALERT: Price-sensitive ASX Announcement for IBX
Current share price for IBX : $0.011 -0.002 (-15.38%)+
Announcement
Release
31 Jul 2026 9:13AM
Price at Release
$0.013
Full Release
download
Summary
Imagion Biosystems Limited released its Appendix 4C Quarterly Activities Report for the quarter ending 30 June 2026. Significant progress was made with the FDA clearance for their Investigational New Drug application for the MagSense® HER2 Imaging Agent, allowing a Phase 1b/2 clinical study to proceed. The company secured $3.75 million in funding commitments to commence this trial. A collaboration with Siemens Healthineers was extended to support the clinical trial. The report also outlines the company's financials, showing a cash balance of AU$32K and anticipating higher operational cash outflows in the upcoming quarter due to clinical study initiation.
Key Points
  • FDA clearance for MagSense® HER2 Imaging Agent.
  • Phase 1b/2 clinical study approval for HER2 positive breast cancer.
  • Extension of collaboration with Siemens Healthineers.
  • Secured $3.75M in funding commitments for clinical trials.
  • Reported cash balance of AU$32K as of 30 June 2026.
  • Anticipation of increased operational cash outflows.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.